Akari Therapeutics has formed a strategic partnership with WuXi XDC to accelerate the development of its novel PH1 payload, an antibody drug conjugate (ADC) targeting RNA splicing in cancer cells. This collaboration aims to advance Akari’s lead candidate, AKTX-101, which targets metastatic urothelial cancer, into clinical trials by late 2026 or early 2027. The PH1 payload offers a unique mechanism by disrupting RNA splicing and activating immune responses, potentially improving treatment outcomes over traditional ADC therapies. WuXi XDC's expertise in ADC development is expected to help Akari validate and commercialize this innovative cancer therapy more rapidly.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Zcash (ZEC) has gained over 16% in the past week, rallying from lows near $368 to around $552 following an 11% jump in one session. This surge is driven by anticipation of the Ironwood shielded pool upgrade expected around July 28, which addresses a ...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
